An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Sponsor
PDL BioPharma, Inc. (Industry)
Overall Status
Terminated
CT.gov ID
NCT00355901
Collaborator
(none)
300
40
74
7.5
0.1

Study Details

Study Description

Brief Summary

To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.

Condition or Disease Intervention/Treatment Phase
  • Drug: Visilizumab (Nuvion®; HuM291)

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Time Perspective:
Prospective
Official Title:
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
Study Start Date :
Sep 1, 2006
Study Completion Date :
Nov 1, 2012

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Previous participation in a visilizumab study of IVSR-UC.

    • Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy.

    Exclusion Criteria:
    • Unable to understand the purpose and risks of the study, or unwilling or unable to provide a signed and dated informed consent.

    • For U.S. sites, unwilling or unable to provide authorization to use protected health information.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 San Francisco California United States 94115
    2 Gainesville Florida United States 32610
    3 Atlanta Georgia United States 30342
    4 Louisville Kentucky United States 40202
    5 Worcester Massachusetts United States 01655
    6 Rochester Minnesota United States 55905
    7 St. Louis Missouri United States 63110
    8 Manhasset New York United States 11030
    9 Mineola New York United States 11501
    10 New York New York United States 10021
    11 New York New York United States 10029
    12 Cleveland Ohio United States 44106
    13 Hershey Pennsylvania United States 17033
    14 Charleston South Carolina United States 29425
    15 Salt Lake City Utah United States 84107
    16 Bedford Park South Australia Australia
    17 Box Hill Victoria Australia
    18 Fremantle Australia 6160
    19 Liverpool Australia 2170
    20 Wien Austria A-1090
    21 Ghent Belgium B-9000
    22 Leuven Belgium 3000
    23 Roeselare Belgium 8800
    24 Winnipeg Manitoba Canada R3A-139
    25 Hamilton Ontario Canada L8N 3Z5
    26 Brno Czech Republic
    27 Praha Czech Republic
    28 Amiens Cedex France 80054
    29 Lille France 59037
    30 Paris France 75010
    31 Freiburg Germany D-79106
    32 Béri Balogh Adám Hungary H-7100
    33 Vac Hungary H-2601
    34 Vásvari Pál Hungary H-9024
    35 Dublin Ireland
    36 Bologna Italy 40138
    37 Amsterdam Netherlands 1105 AZ
    38 Oslo Norway
    39 Tromso Norway
    40 Kharkov Ukraine 61001

    Sponsors and Collaborators

    • PDL BioPharma, Inc.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00355901
    Other Study ID Numbers:
    • 291-420
    First Posted:
    Jul 25, 2006
    Last Update Posted:
    Aug 5, 2008
    Last Verified:
    Aug 1, 2008

    Study Results

    No Results Posted as of Aug 5, 2008